<DOC>
	<DOCNO>NCT00153842</DOCNO>
	<brief_summary>The primary aim evaluate safety ( Phase I component ) administer bexarotene ( Targretin® , LGD1069 ) oral capsule combination two Taxol® carboplatin ( Paraplatin® ) schedule patient stage IIIB IV non-small cell lung cancer . This study also evaluate preliminary efficacy ( Phase II component ) bexarotene oral capsule combination weekly Taxol® schedule carboplatin patient .</brief_summary>
	<brief_title>A Study Paclitaxel Carboplatin Combination With Bexarotene Oral Capsules Patients With Advanced Lung Cancer</brief_title>
	<detailed_description>The phase I portion study evaluate safety administer bexarotene oral capsule daily two dose level ( 300 mg/m2 400 mg/m2 ) combination carboplatin Taxol® . At least 6 patient enter onto dose level . Doses escalate course treatment individual patient . The recommended Phase II dose define high dose bexarotene oral capsule ( 300 mg/m2 400 mg/m2 ) combination carboplatin Taxol® induce DLT few equal 33 % patient . The sequential phase II portion study evaluate efficacy bexarotene oral capsule combination carboplatin weekly Taxol® patient advance non-small cell lung cancer . The efficacy gauge accord rate major response , definition , major response occur patient achieves either complete remission ( CR ) partial remission ( PR ) . For patient true response rate 20 % great sufficiently large warrant investigation . A true response rate 10 % less indicate combination less active .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>unresectable stage IIIB IV NSCLC adequate bone marrow , hepatic , thyroid renal function peripheral neuropathy &gt; = grade 2 gastrointestinal abnormality know hypersensitivity retinoids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Bexarotene</keyword>
	<keyword>Targretin</keyword>
</DOC>